Innoviva, Inc. INVA
Price
Full chart with drawing tools and indicators
Valuation and ratios (P/E, margins, market value)
Price charts and figures by TradingView, shown in a sealed box: it cannot read this page, but TradingView may count your visit. Prices can be delayed.
Results from SEC filings
| Revenue | $411.3M | +15% | FY ending Dec 31, 2025 |
|---|---|---|---|
| Gross profit | $307.7M | +4% | FY ending Dec 31, 2025 |
| Operating income | $163.7M | -2% | FY ending Dec 31, 2025 |
| Net income | $271.2M | +1059% | FY ending Dec 31, 2025 |
| Earnings per share | $3.30 | +817% | FY ending Dec 31, 2025 |
| Research & development | $30.6M | +124% | FY ending Dec 31, 2025 |
| Cash from operations | $196.9M | +4% | FY ending Dec 31, 2025 |
| Capital spending | $1.1M | +319% | FY ending Dec 31, 2025 |
| Share buybacks | $4.5M | -69% | FY ending Dec 31, 2025 |
| Dividends paid | $0 | FY ending Dec 31, 2021 | |
| Cash | $550.9M | +81% | FY ending Dec 31, 2025 |
| Long-term debt | $257.7M | +1% | FY ending Dec 31, 2025 |
| Shareholders' equity | $1.2B | +70% | FY ending Dec 31, 2025 |
| Shares outstanding | 75M | +19% | FY ending Dec 31, 2025 |
Insider trades
Last 12 months: 0 open-market buys ($0) and 0 sales ($0) by officers, directors and big owners. These are exact: shares times the price each insider reported. Several sales by one person on one day are combined (average price).
Other insider moves (25): pay awards, option exercises, tax withholding, gifts
| Insider | Trade | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Pavel RaifeldChief Executive Officer, Director | Tax withholding | 1,130 | $21.00 | $24K | Aug 20, 2026 |
| Marianne ZhenChief Accounting Officer | Tax withholding | 1,127 | $21.00 | $24K | Aug 20, 2026 |
| Stephen BassoChief Financial Officer | Tax withholding | 558 | $21.00 | $12K | Aug 20, 2026 |
| Pavel RaifeldChief Executive Officer, Director | Tax withholding | 1,130 | $22.24 | $25K | May 20, 2026 |
| Marianne ZhenChief Accounting Officer | Tax withholding | 1,127 | $22.24 | $25K | May 20, 2026 |
| Stephen BassoChief Financial Officer | Tax withholding | 559 | $22.24 | $12K | May 20, 2026 |
| Josephine LindenDirector | Award2 fills | 15,194 | – | – | May 18, 2026 |
| Stephen BassoChief Financial Officer | Award | 1,123 | – | – | May 15, 2026 |
| Pavel RaifeldChief Executive Officer, Director | Award | 1,123 | – | – | May 15, 2026 |
| Mark DipaoloDirector | Award | 9,786 | – | – | May 4, 2026 |
| Pavel RaifeldChief Executive Officer, Director | Award | 126,646 | – | – | May 4, 2026 |
| Marianne ZhenChief Accounting Officer | Award | 12,766 | – | – | May 4, 2026 |
| Sarah J. SchlesingerDirector | Award | 9,786 | – | – | May 4, 2026 |
| Stephen BassoChief Financial Officer | Award | 37,994 | – | – | May 4, 2026 |
| Derek A SmallDirector | Award | 9,786 | – | – | May 4, 2026 |
| Jules HaimovitzDirector | Award | 9,786 | – | – | May 4, 2026 |
| Pavel RaifeldChief Executive Officer, Director | Tax withholding | 2,986 | $23.39 | $70K | Feb 20, 2026 |
| Marianne ZhenChief Accounting Officer | Tax withholding | 2,460 | $23.39 | $58K | Feb 20, 2026 |
| Stephen BassoChief Financial Officer | Tax withholding | 1,244 | $23.39 | $29K | Feb 20, 2026 |
| Marianne ZhenChief Accounting Officer | Tax withholding | 992 | $21.16 | $21K | Nov 20, 2025 |
| Stephen BassoChief Financial Officer | Tax withholding | 237 | $21.16 | $5,015 | Nov 20, 2025 |
| Stephen BassoChief Financial Officer | Award | 604 | – | – | Nov 15, 2025 |
| Pavel Raifeld10% owner | Award | 110,436 | $18.11 | $2.0M | Nov 3, 2025 |
| Stephen BassoChief Financial Officer | Award | 27,609 | $18.11 | $500K | Nov 3, 2025 |
| Pavel Raifeld10% owner | Award | 1,860 | – | – | May 15, 2025 |
Trades by members of Congress
1 member reported 0 buys and 2 sales since Mar 24, 2025. Amounts are legal ranges, not exact figures.
| Member | Trade | Amount | Traded | Reported | Owner |
|---|---|---|---|---|---|
| George Whitesides D | Sold | $250K–$500K | Mar 25, 2025 | Apr 23, 2025 | Spouse |
| George Whitesides D | Sold | $50K–$100K | Mar 24, 2025 | Apr 23, 2025 | Self |
Latest SEC filings
- Quarterly report 10-Q · Aug 5, 2026
- News filing: Quarterly results 8-K · Aug 5, 2026
- News filing: Executive or board change 8-K · May 18, 2026
- Quarterly report 10-Q · May 6, 2026
- News filing: Quarterly results 8-K · May 6, 2026
- News filing: Shareholder vote results 8-K · May 4, 2026
- Shareholder meeting proxy DEF 14A · Mar 24, 2026
- News filing: Quarterly results 8-K · Feb 25, 2026
- Annual report 10-K · Feb 25, 2026
- Quarterly report 10-Q · Nov 5, 2025
- News filing: Quarterly results 8-K · Nov 5, 2025
- Quarterly report 10-Q · Aug 6, 2025
- News filing: Quarterly results 8-K · Aug 6, 2025
- News filing: Shareholder vote results 8-K · May 21, 2025
- Quarterly report 10-Q · May 7, 2025
- News filing: Quarterly results 8-K · May 7, 2025
- Shareholder meeting proxy DEF 14A · Apr 8, 2025
- Annual report 10-K · Feb 26, 2025
- News filing: Quarterly results 8-K · Feb 26, 2025
- Quarterly report 10-Q · Nov 6, 2024
- News filing: Quarterly results 8-K · Nov 6, 2024
- Quarterly report 10-Q · Jul 31, 2024
- News filing: Quarterly results 8-K · Jul 31, 2024
- News filing: Shareholder vote results 8-K · Jun 20, 2024
- Big shareholder stake SC 13G · May 13, 2024
About Innoviva, Inc.
Business description
- Industry
- Pharmaceutical Preparations
- Sector
- Life Sciences
- Headquarters
- Burlingame, CA
- Incorporated in
- DE
- Fiscal year ends
- December 31
- Exchange
- Nasdaq
- Filer size
- Large accelerated filer
- Formerly
- THERAVANCE INC, ADVANCED MEDICINE INC
- SEC company number (CIK)
- 1080014
Company figures and insider trades: U.S. Securities and Exchange Commission (EDGAR). Congress trades: Clerk of the U.S. House of Representatives. Nebula is not affiliated with either and this page is not investment advice.